SAN DIEGO and VANCOUVER, British Columbia, May 3, 2013 /PRNewswire/ -- GenomeDx Biosciences today announced the launch of UroSketch 3D™, an application available in Apple's App Store and designed specifically for the iPad. The app, which provides a three-dimensional model of the prostate, bladder and surrounding organs for use by physicians during consult with their patients, is now available for download and works with any iPad and iPad mini using the iOS 6 software.
UroSketch 3D was developed in collaboration with Vancouver-based Conquer Mobile and a panel of urologists and consists of preset three-dimensional model views, which allow a physician to zoom in on an image and show the image in 360-degree rotation. The application also offers illustration of different tumor stages and other features which currently focus on the prostate. Funding for this project was made possible by a grant from the Industrial Research Assistance Program (IRAP).
"Practicing urologists told us that an easy-to-use visual application would help them better communicate with their patients," said Doug Dolginow, MD, CEO of GenomeDx. "During the development process, our goal was to pay special attention to anatomical features that are relevant during discussion of prostatectomy so that physicians have another tool to communicate with their patients about the potential ramifications of prostate removal."
"The initial conversation when I first tell my patient that he has prostate cancer can be very challenging for both of us. The weight of the news makes it very difficult for him to absorb new information about his prostate cancer and any details regarding management options to follow," said Ali Kasraeian, MD, FACS, of Kasraeian Urology in Jacksonville, Florida. "I think this app will help engage the patient in his personalized prostate cancer conversation and help facilitate better communication and more effective patient understanding, especially since I can send patients home with an image that will reinforce the details of our conversation."
In each view in the UroSketch 3D app, physicians can use a draw and/or highlighter function to mark up images and then email or print out a personalized PDF for patients to take home. The resulting PDF will include a header with physician name, date stamp and any contact details that the physician provides upon download of the app. Consult sessions are listed on the home screen by time and erased at the end of each day to ensure privacy. Physicians may create master sketches, which are not erased and can be used as templates for new sessions.
Come visit GenomeDx at AUA 2013 in booth 2647 and learn more about UroSketch 3D and the Decipehr™ test, a transformative prognostic test that provides a measure of the biological risk of metastatic prostate cancer.
About GenomeDx Biosciences
GenomeDx Biosciences develops and commercializes genomic tests for prostate and other urologic cancers that have a real impact on treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs. The company's first test, Decipher™, is a transformative prognostic test that provides a direct measure of the true biological risk of metastatic prostate cancer independent of PSA and other risk factors. GenomeDx is based in San Diego, California and Vancouver, British Columbia. More information is available at www.genomedx.com.
SOURCE GenomeDx Biosciences